The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP).

Old age was a major prognostic factor for CML survival prior to the introduction of imatinib but now, age only has marginal significance on survival and mainly with very old patients [31] .

also in 5,069 other papers